Plain-English translation of NCT07208344 on ClinicalTrials.gov ↗ ·
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This clinical trial is testing whether infusions of umbilical cord blood mononuclear cells — specialized cells collected from donated umbilical cords — might help slow cognitive decline and improve memory in people with Alzheimer's disease. You would receive a series of five intravenous infusions over five months, either at a low dose, high dose, or a placebo (salt water), depending on which group you're randomly assigned to. Researchers will measure changes in your thinking, memory, and daily functioning, and also look at inflammation markers and Alzheimer's-related proteins in your blood.
Current treatments for Alzheimer's disease have limited effectiveness. This medication is being tested because early research suggests that umbilical cord blood cells may reduce inflammation and promote brain health in ways that could slow memory loss and help people maintain their ability to think and perform daily activities.
You likely qualify if…
You likely don't qualify if…
You will visit the hospital for five intravenous infusions over about five months — four infusions given one week apart, followed by a fifth infusion one month later. Between and after the infusions, you'll have follow-up appointments at 1 month, 2 months, 3 months, and 6 months where researchers will test your memory and thinking, check your blood for inflammation markers and Alzheimer's-related proteins, and assess your ability to perform daily tasks. Blood samples and possibly spinal fluid samples will be collected to help researchers understand how the treatment works.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China